Vaccine responses to influenza viruses and SARS-CoV-2 under novel immunotherapies in myasthenia gravis and CIDP: a prospective observational study
Abstract Patients with myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP) require long-term immunotherapy, making effective vaccination essential for infection prophylaxis. As these immunotherapies increasingly involve novel agents such as FcRn antagonists and complement inhibitors, their influence on the vaccine response needs to be assessed. Therefore, we prospectively enrolled 23 patients with MG or CIDP receiving contemporary immunotherapies who were vaccinated against influenza viruses ( n = 21; Northern Hemisphere 2025/26) or SARS-CoV-2 ( n = 12). Sera collected before and at least two weeks after vaccination were assayed for antibodies against the SARS-CoV-2 spike S1 subunit and three influenza strains. A response to SARS-CoV-2 vaccination (≥ 2-fold increase in anti-S1 IgG) was observed in 9 of 12 patients (75%; median fold-change 2.6), and influenza seroprotection rates (haemagglutination inhibition [HAI] titer ≥ 1:40) rose for all three strains reaching 86% (A/H1N1), 76% (B/Victoria), and 67% (A/H3N2). The effect of individual medications on post-vaccination titers was assessed by analysis of covariance (ANCOVA), adjusting for baseline titer and diagnosis. In these exploratory models, estimates were directionally higher under ravulizumab and lower under efgartigimod and mycophenolate; none remained statistically significant after correction for multiple testing. Patients receiving efgartigimod and mycophenolate concurrently had significantly lower absolute post-vaccination HAI titers for A/H1N1 (median 1:30 vs. 1:160; p = 0.0085) and A/H3N2 (median < 1:10 vs. 1:40; p = 0.022). These findings are consistent with lower baseline and circulating antibody levels and do not show a detectable difference in fold-change in this small exploratory cohort. Patients who failed to seroconvert to any strain were more frequently receiving FcRn antagonists, yet most retained seroprotection against at least one strain. Under FcRn antagonism, influenza titers did not parallel total serum IgG, with several patients seroconverting despite a concurrent decline in total IgG. In conclusion, most patients mounted a measurable humoral response to both vaccines despite contemporary immunotherapy.
Authors
- Stefanie Meyer (ORCID: https://orcid.org/0000-0002-9349-3902)
- Dirk Fitzner (ORCID: https://orcid.org/0000-0002-2511-6216)
- Seyed Siyawasch Justus Lattau (ORCID: https://orcid.org/0000-0002-1595-3408)
- Ralf Dürrwald (ORCID: https://orcid.org/0000-0002-3432-0438)
- Stefanie Glaubitz (ORCID: https://orcid.org/0009-0008-1957-4457)
- Jana Zschüntzsch (ORCID: https://orcid.org/0000-0002-7062-5319)
- Melanie Sylvia Eisele (ORCID: https://orcid.org/0009-0002-7957-1318)
- Fee Aliah Heiler
Institutions
- Robert Koch Institute (DE)
- Universitätsmedizin Göttingen (DE)
- University of Göttingen (DE)
Publication Details
- Journal
- Scientific Reports
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1038/s41598-026-77736-7
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Universitätsmedizin Göttingen
- Deutsche Forschungsgemeinschaft
- Georg-August-Universität Göttingen